We are monitoring the impact of COVID-19 on Influenza Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1621
Share on
Share on

Global Influenza Market Size, Share, Trends & Growth Analysis Report – Segmented By Product Type (Vaccines & Drugs), Consumer and Region – Industry Forecast (2020 to 2025)

Pulished: February, 2020
ID: 1621
Pages: 170

Global Influenza Market Size (2020 to 2025)

The global influenza market size is expected to reach USD 10.59 billion by 2025 from USD 7.03 billion in 2020, growing at a CAGR of 8.54% between 2020 to 2025.

Influenza is a flu or viral infection which affects the respiratory system. The person affected by influenza may suffer from usual symptoms such as headaches, fever, fatigue, cough, muscle aches, congestion, and running nose. There are four types of influenza viruses: type A, B, C, and D. These viruses travel through the respiratory system and can transmit through direct contact or by taking virus-infected air particles. Influenza can be ideally prevented by vaccination. 

MARKET DRIVERS:

increased focus of governments to provide better medical solutions for the people, enhancement of existing vaccines, low risk of side effects associated with influenza vaccines are some of the significant factors that are boosting the growth of the global influenza market.

The other factors that boost the influenza market's growth are increased funding for research and development activities, the emergence of novel vaccines, and the increased prevalence of medical tourism.

The influenza market is expected to provide lucrative growth opportunities for the key players in the market, owing to the increased account of immunization programs at regular intervals. The availability of various influenza vaccines that have been prequalified by the world health organization and bought by united Nations agencies has provided many opportunities for the growth of the global influenza market. It is expected to continue the trend during the forecast period. Many influenza vaccines for treating the influenza A virus in animals are under the development phase, and trials are supposed to be launched over time. Influenza vaccines are being modified specially for seasons to tackle the virus strains, which alter each season; these factors are pushing the significant market players to develop new vaccines at regular intervals to milk the global influenza market opportunities.  

MARKET RESTRAINTS:

The key factors that challenge the growth of the global influenza market are the time required for the production of the vaccine and the manufacturing costs associated with very high development.  

Impact of COVID-19 on the global influenza market:

The COVID-19 epidemic has had a huge impact on countries worldwide, putting a financial strain on the population. The World Health Organization (WHO) declared the coronavirus epidemic a public health emergency in January 2020. Influenza is a viral infection of the respiratory system that causes fever, body aches, runny nose, cough, congestion, headaches, and exhaustion in those that are infected. Influenza, also known as the flu, is a contagious disease caused by a bacterial infection. It is very infectious and spreads mostly by respiratory droplets. The increased emphasis on research activities to produce a vaccine to contain the widespread impact of the novel coronavirus is boosting global demand for immunization. The pandemic of COVID-19 has caused unprecedented changes in the healthcare sector. In the near term, the industry is expected to benefit from increased demand for seasonal influenza vaccines to ensure improved safety against the deadly pandemic. As a result, improved R&D leading to the production of a new COVID-19 vaccine is expected to boost the sales potential of the market. 

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2019 to 2025

Base Year

2019

Forecast Period

2020 to 2025

Segments Covered

By Product Type, Consumer, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Sanofi-Pasteur (U.S.), AstraZeneca (United Kingdom), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan) and CSL Limited (Australia)

 

This research report on the global influenza market has been segmented and sub-segmented based on product type, consumer, and region.

Influenza Market - By Product Type:

  • Vaccines
  • Drugs

Based on product type, the Vaccines (Fluzone, Afluria, Fluvirin, Flublok, and others) segment commands significant market share, estimated to be more than 80% and anticipated to be the fastest-growing segment during the forecast period.

Influenza Market - By Consumer:

  • Children
  • Adults

Influenza Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America is leading the global influenza vaccine market by contributing the largest share of revenues and is expected to continue the trend owing to the factors such as the increased focus of governments on immunization programs, improvements in vaccine administration, increased incidence of influenza in the region, and the influx of new vaccines. LAMEA is another major contributor to the global market and is expected to grow at a high pace during the forecast period due to the factors like an increase in disposable income, advancements of healthcare facilities, and escalated growth of economies.

KEY MARKET PLAYERS:

Some of the promising companies leading the global influenza market profiled in this report are Sanofi-Pasteur (U.S.), AstraZeneca (United Kingdom), F. Hoffmann-La Roche (Switzerland), Novartis (Switzerland), GlaxoSmithKline (U.K.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Abbott Laboratories (U.S.), Mitsubishi Tanabe Pharma Corporation (Japan) and CSL Limited (Australia).

KEY HAPPENINGS IN THIS MARKET IN THE RECENT PAST:

  • ResVax vaccine, a vaccine developed by Novavax Company for RSV diseases, has completed phase 3 of the trial process, and the outcomes were announced at the IDSOG meeting in August 2019.
  • Emergent BioSolutions Company has developed a vaccine called NuThrax anthrax vaccine, for which the company has enrolled patients to begin the phase 3 trial of clinical study in 2018. The vaccine is a combination of anthrax and BioThrax vaccine developed by the Emergent, which improves the body's immune response.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product Type                             

                                5.1.1 Introduction           

                                5.1.2 Vaccines   

                                5.1.3 Drugs         

                                5.1.4  Y-o-Y Growth Analysis, By Product              

                                5.1.5  Market Attractiveness Analysis, By Product            

                                5.1.6  Market Share Analysis, By Product              

                5.2 Type                              

                                5.2.1 Introduction           

                                5.2.2 Safety Biomarkers

                                5.2.3 Efficacy Biomarkers             

                                5.2.4 Validation Biomarkers        

                                5.2.5  Y-o-Y Growth Analysis, By Type    

                                5.2.6  Market Attractiveness Analysis, By Type  

                                5.2.7  Market Share Analysis, By Type    

                5.3 Application                 

                                5.3.1 Introduction           

                                5.3.2 Diagnostics Development 

                                5.3.3 Drug Discovery and Development

                                5.3.4 Personalised Medicine      

                                5.3.5 Disease Risk Assessment  

                                5.3.6 Other Applications               

                                5.3.7  Y-o-Y Growth Analysis, By Application        

                                5.3.8  Market Attractiveness Analysis, By Application      

                                5.3.9  Market Share Analysis, By Application       

                5.4 Disease Indications                 

                                5.4.1 Introduction           

                                5.4.2 Cancer      

                                5.4.3 CardiovascularDisorders    

                                5.4.4 Neurological Disorders       

                                5.4.5 Immunological Disorders  

                                5.4.6 Other Diseases      

                                5.4.7  Y-o-Y Growth Analysis, By Disease Indications        

                                5.4.8  Market Attractiveness Analysis, By Disease Indications 

                                5.4.9  Market Share Analysis, By Disease Indications 

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Type

                                                6.1.3.4 By Application

                                                6.1.3.5 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Type

                                                6.1.4.4 By Application

                                                6.1.4.5 By Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Type

                                                6.1.5.4 By Application

                                                6.1.5.5 By Indication

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Sanofi-Pasteur                          

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 AstraZeneca                               

                8.3 F. Hoffmann-La Roche                           

                8.4 Novartis                       

                8.5 GlaxoSmithKline                       

                8.6 Pfizer Inc.                    

                8.7 Merck & Co.                               

                8.8 Abbott Laboratories                               

                8.9 Mitsubishi Tanabe Pharma Corporation                         

                8.10 CSL Limited                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Influenza Market, By Region, From 2020 to 2025 (USD Million)
  2. Global Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  3. Global Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  4. Global Drugs Market, By Region, From 2020 to 2025 (USD Million)
  5. Global Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  6. Global Children Market, By Region, From 2020 to 2025 (USD Million)
  7. Global Adults Market, By Region, From 2020 to 2025 (USD Million)
  8. North America Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  9. North America Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  10. North America Drugs Market, By Region, From 2020 to 2025 (USD Million)
  11. North America Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  12. North America Children Market, By Region, From 2020 to 2025 (USD Million)
  13. North America Adults Market, By Region, From 2020 to 2025 (USD Million)
  14. United States Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  15. United States Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  16. Canada Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  17. Canada Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  18. Europe Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  19. Europe Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  20. Europe Drugs Market, By Region, From 2020 to 2025 (USD Million)
  21. Europe Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  22. Europe Children Market, By Region, From 2020 to 2025 (USD Million)
  23. Europe Adults Market, By Region, From 2020 to 2025 (USD Million)
  24. U.K. Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  25. U.K. Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  26. Germany Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  27. Germany Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  28. France Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  29. France Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  30. Italy Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  31. Italy Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  32. Spain Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  33. Spain Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  34. Asia-Pacific Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  35. Asia-Pacific Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  36. Asia-Pacific Drugs Market, By Region, From 2020 to 2025 (USD Million)
  37. Asia-Pacific Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  38. Asia-Pacific Children Market, By Region, From 2020 to 2025 (USD Million)
  39. Asia-Pacific Adults Market, By Region, From 2020 to 2025 (USD Million)
  40. Japan Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  41. Japan Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  42. China Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  43. China Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  44. India Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  45. India Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  46. Australia Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  47. Australia Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  48. South Korea Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  49. South Korea Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  50. Latin America Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  51. Latin America Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  52. Latin America Drugs Market, By Region, From 2020 to 2025 (USD Million)
  53. Latin America Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  54. Latin America Children Market, By Region, From 2020 to 2025 (USD Million)
  55. Latin America Adults Market, By Region, From 2020 to 2025 (USD Million)
  56. Brazil Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  57. Brazil Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  58. Argentina Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  59. Argentina Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  60. Mexico Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  61. Mexico Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  62. Rest of Latin America Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  63. Rest of Latin America Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  64. Middle East & Africa Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  65. Middle East & Africa Vaccines Market, By Region, From 2020 to 2025 (USD Million)
  66. Middle East & Africa Drugs Market, By Region, From 2020 to 2025 (USD Million)
  67. Middle East & Africa Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  68. Middle East & Africa Children Market, By Region, From 2020 to 2025 (USD Million)
  69. Middle East & Africa Adults Market, By Region, From 2020 to 2025 (USD Million)
  70. Middle East Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  71. Middle East Influenza Market, By Consumer, From 2020 to 2025 (USD Million)
  72. Africa Influenza Market, By Product Type, From 2020 to 2025 (USD Million)
  73. Africa Influenza Market, By Consumer, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample